This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (15)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • General Rhinology  • Paranasal Sinus Disease  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Jan Gosepath, MD; Dirk Schaefer, MS; Ronald G. Amedee, MD; Wolf J. Mann, MD

Arch Otolaryngol Head Neck Surg. 2001;127:316-321.

Background  Patients with aspirin-sensitive rhinosinusitis, which is frequently associated with intrinsic bronchial asthma, can be desensitized by long-term treatment with oral aspirin. The exact mechanisms of this desensitization remain obscure, but modulations of the eicosanoid pathway occur and can be monitored with the help of a practicable in vitro assay on mixed leukocyte cultures.

Objective  To monitor the effect of low-dose aspirin desensitization therapy, 100 mg/d, objectively by an in vitro assay.

Design  In a prospective study, 30 patients with aspirin intolerance, who were treated following a desensitization protocol with a dose of oral aspirin of only 100 mg/d were followed up for 1 year and reassessed every 3 months clinically and in vitro.

Results  Twenty-five patients showed a normalization of in vitro eicosanoid levels during this period, 4 showed some improvement, and 1 showed no therapeutic effect on eicosanoid release. Clinical follow-up revealed a low recurrence rate of nasal polyposis, with recurrent disease only in 4 individuals who also showed no normalization of eicosanoid release levels. Furthermore, a reduction of the average incidence of purulent episodes of sinusitis was seen after 1 year. Of 12 patients with asthma, 9 experienced marked improvement in pulmonary function. Of 16 individuals with a marked impairment of nasal breathing, 14 felt an increase of nasal patency, and 7 of 11 patients with pretreatment hyposmia had an improved sense of smell after 1 year.

Conclusions  Desensitization therapy in patients with aspirin-sensitive rhinosinusitis can be successfully performed with low oral doses of aspirin, and the individual course throughout the desensitization can be monitored with the help of an in vitro analysis of eicosanoid release from mixed leukocyte cultures.

From the Departments of Otolaryngology–Head and Neck Surgery, Mainz Medical School, Mainz, Germany (Drs Gosepath and Mann and Mr Schaefer); and Tulane University, School of Medicine, New Orleans, La (Dr Amedee).

Corresponding author and reprints: Jan Gosepath, MD, Department of Otolaryngology–Head and Neck Surgery, Mainz Medical School, Langenbeckstrasse 1, 55101 Mainz, Germany (e-mail: gosepath{at}hno.klinik.uni-mainz.de).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLE

Archives of Otolaryngology–Head & Neck Surgery Reader's Choice: Continuing Medical Education
Arch Otolaryngol Head Neck Surg. 2001;127(3):342-343.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management Options for Patients with Aspirin and Nonsteroidal Antiinflammatory Drug Sensitivity
Knowles et al.
The Annals of Pharmacotherapy 2007;41:1191-1200.
ABSTRACT | FULL TEXT  

Aspirin Desensitization for Chronic Hyperplastic Sinusitis, Nasal Polyposis, and Asthma Triad
Mardiney and Borish
Arch Otolaryngol Head Neck Surg 2001;127:1287-1287.
FULL TEXT